Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

Annals of the Rheumatic Diseases

Volumn 76, Issue 12, 2017, Pages 1986-1991

  Emery, Paul ^a,b   Vencovský, Jiří ^c   Sylwestrzak, Anna ^d   Leszczyński, Piotr ^e   Porawska, Wieslawa ^f   Stasiuk, Barbara ^f   Hilt, Joanna ^f   Mosterova, Zdenka ^g   Cheong, Soo Yeon ^h   Ghil, Jeehoon ^h  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^d NZOZ Centrum Medyczne   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f Poznanski Osrodek Medyczny NOVAMED   (Poland)

^g Rheumatology   (Czech Republic)

^h Samsung Bioepis Co Ltd   (South Korea)

Author keywords

anti TNF; DMARDs (biologic); rheumatoid arthritis; TNF alpha; treatment

Indexed keywords

ETANERCEPT; METHOTREXATE;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; HYPERTENSION; IMMUNOGENICITY; INJECTION SITE REACTION; LARYNGITIS; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 85038082940     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211591     Document Type: Article

References (22)

1. Scott LJ. Etanercept: A review of its use in autoimmune inflammatory diseases. Drugs 2014;74:1379-410.
2. Enbrel®. Etanercept. Thousand Oaks, CA: Immunex Corporation, 2016.
3. Enbrel® (etanercept). Product characteristics 2016.
4. Cho IH, Lee N, Song D, et al. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. MAbs 2016;8:1136-55.
5. Lee YJ, Shin D, Kim Y, et al. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel) in healthy subjects. Br J Clin Pharmacol 2016;82:64-73.
6. Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017;76:51-7.
7. Vencovsky J, Sylwestrzak A, Leszczynski P, et al. A phase III, randomized, doubleblind clinical study comparing SB4, an etanercept biosimilar, with etanercept reference product (Enbrel) in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (52-week results) [abstract]. Arthritis Rheumatol 2015;67:2444-6.
8. Benepali®(etanercept). Product characteristics 2016.
9. Brenzys™ (etanercept). Product monograph 2016.
10. van der Heijde D. How to read radiographs according to the sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
11. Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study. Arthritis Rheum 2010;62:674-82.
12. Keystone EC, Pope JE, Thorne JC, et al. Two-year radiographic and clinical outcomes from the Canadian methotrexate and etanercept outcome study in patients with rheumatoid arthritis. Rheumatology 2016;55:327-34.
13. van der Heijde D, Klareskog L, Landewé R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39.
14. D ore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:40-6.
15. Klareskog L, Gaubitz M, Rodríguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:238-47.
16. Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008;58:1921-30.
17. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017;76:355-63.
18. P ark W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017;76:346-54.
19. Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017;389:2304-16.
20. Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017;76:1426-31.
21. Glintborg B, Sorensen IJ, Loft AG, et al. Clinical outcomes from a nationwide nonmedical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. Results from the Danbio registry. Ann Rheum Dis 2017;76:553.
22. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-7.